Division of Neuromuscular Medicine, Department of Neurology, Duke University Medical Center, Durham, North Carolina.
Division of Neuromuscular Medicine, Department of Neurology, Duke University Medical Center, Durham, North Carolina.
Ann Thorac Surg. 2022 Mar;113(3):904-910. doi: 10.1016/j.athoracsur.2021.06.071. Epub 2021 Jul 30.
There is clinical equipoise regarding the perioperative and long-term outcomes of autoimmune myasthenia gravis (MG) patients undergoing open vs minimally invasive thymectomy, particularly for nonthymomatous MG. This analysis utilizes multicenter, real-world clinical evidence to assess perioperative complications of open and minimally invasive thymectomy techniques in MG patients.
Thymectomy cases from 2009 to 2019 in MG patients were identified in The Society of Thoracic Surgeons General Thoracic Surgery Database. Thymectomies were grouped by surgical technique: transthoracic (TT), transcervical (TC), video-assisted thoracoscopic surgery (VATS), or robotic VATS (RVATS). Multivariable logistic regression models assessed the association between surgical technique and perioperative complications.
Analysis of nonthymomatous cases (n = 1725) revealed VATS (odds ratio [OR], 0.44; 95% confidence interval [CI], 0.23-0.83), RVATS (OR, 0.73; 95% CI, 0.48-1.26), and TC (OR, 0.19; 95% CI, 0.06-0.62) thymectomies had lower odds of perioperative complications than TT thymectomies. VATS (OR, 2.29; 95% CI, 0.63-8.30) and RVATS (OR, 4.08; 95% CI,1.21-3.78) thymectomies had higher odds of perioperative complications than TC thymectomies. Analysis of thymomatous cases (n = 311) found no significant difference in the odds of perioperative complications in TT vs minimally invasive (VATS/RVATS) procedures. The proportion of RVATS procedures increased from 6.43% to 44.27%, while TT (56.43% to 34.35%) and TC (19.29% to 6.87%) thymectomies decreased.
Minimally invasive and TC thymectomies have fewer perioperative complications than TT thymectomies when performed for nonthymomatous MG. Minimally invasive procedures are increasingly performed for both nonthymomatous and thymomatous disease. There is a nationwide shift toward minimally invasive procedures, even for thymoma resections. Long-term neurological outcome data are needed to determine whether a reduced perioperative risk for minimally invasive thymectomies translates to improved MG outcomes.
对于接受开胸与微创胸腺切除术的自身免疫性重症肌无力(MG)患者,其围手术期和长期结局存在临床争议,尤其是对于非胸腺瘤性 MG 患者。本分析利用多中心真实世界临床数据,评估了 MG 患者开胸和微创胸腺切除术的围手术期并发症。
在胸外科医师学会胸外科数据库中,确定了 2009 年至 2019 年 MG 患者的胸腺切除术病例。根据手术技术将胸腺切除术分为经胸(TT)、经颈(TC)、电视辅助胸腔镜手术(VATS)或机器人 VATS(RVATS)。多变量逻辑回归模型评估了手术技术与围手术期并发症之间的关系。
对非胸腺瘤病例(n=1725)的分析显示,VATS(比值比 [OR],0.44;95%置信区间 [CI],0.23-0.83)、RVATS(OR,0.73;95%CI,0.48-1.26)和 TC(OR,0.19;95%CI,0.06-0.62)胸腺切除术的围手术期并发症发生风险低于 TT 胸腺切除术。VATS(OR,2.29;95%CI,0.63-8.30)和 RVATS(OR,4.08;95%CI,1.21-3.78)胸腺切除术的围手术期并发症发生风险高于 TC 胸腺切除术。对胸腺瘤病例(n=311)的分析发现,TT 与微创(VATS/RVATS)手术的围手术期并发症发生率无显著差异。RVATS 手术的比例从 6.43%增加到 44.27%,而 TT(56.43%至 34.35%)和 TC(19.29%至 6.87%)胸腺切除术的比例则下降。
对于非胸腺瘤性 MG 患者,微创和 TC 胸腺切除术的围手术期并发症少于 TT 胸腺切除术。微创和 TC 手术越来越多地用于治疗非胸腺瘤性和胸腺瘤性疾病。微创手术在全国范围内普及,甚至用于胸腺瘤切除术。需要长期的神经学结局数据来确定微创胸腺切除术的围手术期风险降低是否能转化为改善 MG 结局。